Bio-Rad Laboratories, Inc.
BIOB
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.92% | 0.65% | -0.88% | -0.33% | -2.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.92% | 0.65% | -0.88% | -0.33% | -2.46% |
| Cost of Revenue | 6.82% | 6.08% | 2.82% | 1.09% | -3.82% |
| Gross Profit | -2.24% | -3.92% | -3.97% | -1.53% | -1.27% |
| SG&A Expenses | 3.76% | 3.10% | 1.14% | 0.38% | -2.18% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.93% | 3.21% | 2.13% | 4.03% | 0.11% |
| Operating Income | -6.89% | -19.50% | -22.62% | -28.96% | -20.29% |
| Income Before Tax | 108.08% | 142.50% | 16.18% | 126.02% | -519.65% |
| Income Tax Expenses | 109.13% | 147.28% | 26.41% | 132.39% | -382.52% |
| Earnings from Continuing Operations | 107.80% | 141.20% | 13.20% | 124.08% | -571.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 107.80% | 141.20% | 13.20% | 124.08% | -571.33% |
| EBIT | -6.89% | -19.50% | -22.62% | -28.96% | -20.29% |
| EBITDA | -0.58% | -9.66% | -12.60% | -18.34% | -12.90% |
| EPS Basic | 108.02% | 143.01% | 10.93% | 125.03% | -637.13% |
| Normalized Basic EPS | -4.09% | -9.94% | -17.77% | -25.72% | -16.34% |
| EPS Diluted | 107.96% | 142.91% | 11.09% | 124.94% | -634.96% |
| Normalized Diluted EPS | -4.09% | -9.94% | -17.73% | -25.64% | -16.25% |
| Average Basic Shares Outstanding | -3.74% | -3.36% | -3.14% | -3.22% | -3.01% |
| Average Diluted Shares Outstanding | -3.75% | -3.36% | -3.19% | -3.31% | -3.10% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |